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hrombin is the ultimate protease in the coagulation cascade
hose pleiotropic actions can lead to thrombosis after tissue
njury. Thrombin is the key effector of the coagulation
ascade and converts fibrinogen to fibrin, which is essential
or laying the meshwork for clot formation. In addition,
hrombin displays a diverse range of effects in vascular cells
hat functionally connects tissue damage to both hemostatic
nd inflammatory responses (1,2). The majority of the
ellular effects of thrombin are initiated via activation of a
amily of protease-activated receptors (PARs), which are
oupled to heterotrimeric G proteins. The PARs are unique
mong G protein-coupled receptors (GPCRs) in that they
re activated by proteases through proteolytic generation
f a tethered ligand (3–5). Thrombin cleaves at the con-
erved arginine residue of the N-terminus of PAR-1, -3,
nd -4 to unleash the tethered ligand that activates the
eceptor. Specific activation of PARs can be achieved by
ynthesizing peptides that mimic the tethered ligand for
ach of the PARs.
See page 1749
Similar to the vascular effects of many other GPCRs,
hrombin has been known to cause endothelium-dependent
rterial vasodilatation since the early 1980s (6,7). Since
AR-1 was first cloned in 1991, multiple groups have
stablished that thrombin activation of PAR-1 promotes
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.(
From the Division of Cardiovascular Medicine, Vanderbilt University Medical
enter, Nashville, Tennessee.rterial vasodilatation in mammals and activation of plate-
ets ex vivo. However, the clinical applicability of many of
hese prior studies is questionable because the human
tudies examining arterial vasoreactivity were conducted in
itro using isolated coronary rings. Furthermore, the in vivo
tudies showing PAR-1 activation of arterial vasodilatation
ere conducted in dogs or rodents. Recently, Newby et al.
8) showed for the first time that infusion of a PAR-1
ctivating peptide in normal human brachial arteries pro-
uces arterial vasodilatation, venoconstriction, activation of
latelets, and release of tissue-type plasminogen activator
t-PA). This investigation established that in vivo activation
f PAR-1 caused these diverse, powerful effects in the
uman forearm vasculature. Although these studies were
uite provocative and convincing, the cautious interpreta-
ion of these findings requires consideration of the possibil-
ty that PAR-1 activation of platelets releases vasoactive
ubstances that account for the observed alterations in
rterial and venous vasoreactivity.
In this issue of the Journal, Gu mundsdo´ttir et al. (9)
onfirm and extend their observations describing the selec-
ive effects PAR-1 activation in vivo in humans. The
ndothelium regulates the tone of vascular smooth muscle via
roduction of endogenous vasodilators. The endothelium-
erived relaxing factors (EDRF) include nitric oxide (NO),
ndothelium-derived hyperpolarizing factor (EDHF), and
rostacyclin. Gu mundsdo´ttir et al. (9) show that PAR-1–
ependent arterial vasodilatation is dependent on the endothe-
ium, because inhibition of NO and EDHF nearly completely
ttenuated the vasodilator response (Fig. 1). Importantly,
nhibition of prostacyclin production with aspirin did not
lter PAR-1–mediated arterial vasodilatation. In contrast,
enudation of the venous endothelium failed to influence
AR-1–mediated venoconstriction. Interestingly, inhibi-
ion of NO production augmented PAR-1–mediated t-PA
elease. This intriguing finding is consistent with prior
tudies indicating that NO decreases von Willebrand factor
vWF) secretion in cultured endothelial cells (10). Endo-
helial cells contain elongated endothelial storage vesicles
alled Weibel-Palade bodies (WPB), which are involved in
he regulated secretion of mature vWF (11,12). The con-
ents of WPBs also include premature vWF, P-selectin, and
ossibly t-PA (13). The vWF facilitates platelet aggregation
t sites of vascular injury (14), and P-selectin mediates
dhesion of leukocytes to endothelial cells (15). Both of
hese molecules are linked to endothelial pathology. The
WF has been proposed to be a marker of endothelial cell
ysfunction, and elevated levels of vWF predict adverse
utcomes in patients with acute coronary syndromes
16,17). Intriguingly, the in vivo activation of PAR-1 in the
uman forearm model stimulated a rapid and robust release
f t-PA, but not vWF (8). These functional differences may
ave a structural explanation, as it has been reported that
-PA is stored in small, dense vesicles distinct from WPBs
18). This observation is debatable because other studies
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Editorial Comment May 6, 2008:1757–9ave shown that t-PA is stored in WPBs in human
ndothelial umbilical vein cells (HUVEC) (19–21). How-
ver, we have shown previously that stimulation of PAR-1 in
UVEC cells causes robust release of vWF (21,22). Further-
ore, other groups have reported that either thrombin or
AR-1 mediated the release of vWF in a variety of different
ndothelial cells, including arterial endothelial cells.
Initial studies using the administration of a specific antag-
nist to PAR-1, designated thrombin receptor antagonists
TRA), have shown promise in patients undergoing percuta-
eous coronary intervention (PCI). With increasing numbers
f PCIs performed in patients with acute coronary syndrome
ACS) (23), bleeding complications are increasingly a major
oncern in this era of aggressive, multimodality antiplatelet and
oagulation therapies. An agent that has the capacity to
electively block the inflammatory and thrombotic effects of
hrombin by preventing PAR activation, without altering the
Figure 1 Schematic Representation of Effects
of PAR-1 Activation on Endothelial Function
For simplicity, thrombin-mediated activation of platelet aggregation medi-
ated via by PAR-1 and PAR-4 in humans is not depicted as is thrombin/
thombomodulin stimulation of the EPCR–APC–PAR-1 complex on the
endothelium. APC  activated protein C; EDHF  endothelium-derived
hyperpolarizing factor; EPCR  endothelial protein C receptor; NO  nitric
oxide; PAR  protease-activated receptors; t-PA  tissue-type plasminogen
activator; vWF  von Willebrand factor. Figure illustration by Rob Flewell.rotective activated protein C pathway or inhibiting fibrin
eneration, could potentially have a more desirable risk–benefit
atio. Indeed, the new oral PAR-1 TRA, SCH530348, has not
een associated with an increase in minor or major bleeding in
atients undergoing PCI when the agent was added to stan-
ard antiplatelet therapy (aspirin and clopidogrel). In addition,
dministration of this TRA has been reported to be associated
ith a trend (nonsignificant) toward reduced ischemic
vents. Based on this and other phase II data, the U.S.
ood and Drug Administration has granted fast-track
esignation for a phase III clinical trial powered to test
he effectiveness of SCH530348 for the reduction of
schemic events. Whether the inhibition of PAR-1–
nduced arterial vasodilatation and t-PA secretion has
dverse consequences in comparison with the potential
eneficial antiplatelet effects is unknown.
eprint requests and correspondence: Dr. Douglas E. Vaughan,
ivision of Cardiovascular Medicine, Vanderbilt University Med-
cal Center, 2220 Pierce Avenue, PRB 383, Nashville, Tennessee
7232. E-mail: doug.vaughan@vanderbilt.edu.
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